# A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT03398148** · PHASE2,PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 1558 (actual)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** risankizumab IV
- **DRUG:** placebo for risankizumab
- **DRUG:** risankizumab SC

## Key facts

- **NCT ID:** NCT03398148
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-07
- **Primary completion:** 2022-11-09
- **Final completion:** 2023-05-11
- **Target enrollment:** 1558 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03398148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03398148, "A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03398148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*